Skip to main content
. Author manuscript; available in PMC: 2014 Jan 7.
Published in final edited form as: Pharmacotherapy. 2012 Apr;32(4):323–332. doi: 10.1002/PHAR.1048

Figure 3.

Figure 3

Cost-effectiveness acceptability curves derived from plots of the percentage of time a therapy is cost-effective over a range of values that a private payer would be willing to pay (horizontal axis) for cytochrome P450 (CYP) 2C19 genotype-guided antiplatelet therapy (incorporating generic clopidogrel) compared with generic clopidogrel or prasugrel. This plot indicates that a willingness-to-pay threshold of approximately $3700 to avoid an event will result in 95% certainty that one of these events will be avoided when using CYP2C19 genotyping compared with generic clopidogrel for all patients. However, to be 95% certain that an event will be avoided when using CYP2C19 genotyping compared with prasugrel for all patients, a private payer must be willing to pay approximately $55,000 to avoid one event.